ABL1 and acute lymphoblastic leukemia: Some BCL2 inhibitors (venetoclax or ABT-199, navitoclax or ABT-263 and ABT-737) have achieved favorable outcomes in specific pediatric ALL groups, especially in ETP-ALL, hypodiploid B-ALL and BCR-ABL1-positive cases; this confirms a major role for BCL2 and the miR-16 precursor family (miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195 and miR-497) in leukemogenesis and apoptosis [191,192].